Enveda
Provider of an AI platform for drug discovery, centered on PRISM, a foundation model trained on the chemistry of living organisms.
- Industry
- AI platform for drug discovery
- Location
- Boulder, CO
About
Enveda is described in the cited sources as a Boulder, CO-based provider of an AI platform for drug discovery. The platform is centered on PRISM, a foundation model trained on the chemistry of living organisms. It is used to identify and test naturally occurring molecules, with the aim of developing oral medicines for inflammatory and metabolic conditions.
FinSMEs reports that the company intends to use the Series E funds to advance ENV-294 and ENV-308 into later-stage trials, advance ENV-6946 through mid-phase trials, and scale PRISM and the automated laboratory that feeds it.
Funding history
| Round | Date | Amount | Lead |
|---|---|---|---|
| Series E 2026 | 2026-09-23 | $311M | Catalio Capital Management |
Investors
- Catalio Capital Management lead
- Durable Capital Partners participant
- ICONIQ participant
- Lightspeed participant
- Surveyor Capital participant
- Accounts advised by T. Rowe Price Investment Management participant
- Digitalis Ventures participant
- Alderline Group participant
- Baillie Gifford participant
- Premji Invest participant
- FPV Ventures participant
- True Ventures participant
- Kinnevik participant
- Dimension participant
- Lifeforce Capital participant
- Lux Capital participant
Sources
Last verified:
- https://www.finsmes.com/2026/09/enveda-raises-311m-in-series-e-funding.html
Type: reputable publication. Accessed 2026-09-23.
FinSMEs article dated 2026-09-23. Source of the description, location, round, amount and investor names. - https://techcrunch.com/2026/09/23/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-into-clinical-trials/
Type: reputable publication. Accessed 2026-09-23.
Named as the corroborating source by the Raise Track pipeline verifier (status verified, 2026-09-23). Not re-read when this page was written.